Abbott Laboratories (NYSE:ABT – Free Report) – Research analysts at William Blair decreased their Q1 2025 earnings estimates for Abbott Laboratories in a research report issued on Thursday, January 23rd. William Blair analyst M. Andrew now forecasts that the healthcare product maker will post earnings of $1.07 per share for the quarter, down from their prior forecast of $1.10. The consensus estimate for Abbott Laboratories’ current full-year earnings is $5.15 per share. William Blair also issued estimates for Abbott Laboratories’ Q2 2025 earnings at $1.23 EPS, Q4 2025 earnings at $1.53 EPS, FY2025 earnings at $5.15 EPS, Q1 2026 earnings at $1.18 EPS, Q2 2026 earnings at $1.37 EPS, Q3 2026 earnings at $1.49 EPS, Q4 2026 earnings at $1.67 EPS and FY2026 earnings at $5.71 EPS.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11,029,400 billion. During the same period in the prior year, the company earned $1.19 earnings per share. The company’s revenue was up 7.2% on a year-over-year basis.
Read Our Latest Stock Report on ABT
Abbott Laboratories Stock Performance
Shares of NYSE ABT opened at $125.12 on Friday. The stock has a market cap of $217.01 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 2.51 and a beta of 0.73. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $125.67. The company has a 50 day simple moving average of $115.07 and a two-hundred day simple moving average of $113.15. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.
Institutional Investors Weigh In On Abbott Laboratories
A number of large investors have recently modified their holdings of ABT. Future Financial Wealth Managment LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $31,000. Peterson Financial Group Inc. purchased a new position in Abbott Laboratories during the third quarter worth approximately $32,000. Valued Wealth Advisors LLC grew its holdings in Abbott Laboratories by 78.4% in the 3rd quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after buying an additional 127 shares in the last quarter. Highline Wealth Partners LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter worth $37,000. Finally, JDM Financial Group LLC boosted its position in shares of Abbott Laboratories by 51.3% during the 3rd quarter. JDM Financial Group LLC now owns 363 shares of the healthcare product maker’s stock valued at $41,000 after acquiring an additional 123 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Abbott Laboratories Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $0.59 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a yield of 1.89%. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio is currently 30.85%.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Learn Technical Analysis Skills to Master the Stock Market
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- How to invest in marijuana stocks in 7 steps
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Stock Average Calculator
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.